• Emerge
  • Posts
  • 🚀 Economists Question White House's Tariff Income Claims

🚀 Economists Question White House's Tariff Income Claims

In partnership with

Own shares in a revolutionary sleep technology startup.

Smart Nora’s patented solution has already brought better sleep to more than 100,000 customers. The company is now bringing this technology to millions of people who can not tolerate CPAPs and other invasive snoring and sleep apnea solutions. Sleep apnea awareness and detection are at all times high. This is the perfect opportunity to join them.

Read the Offering information carefully before investing. It contains details of the issuer’s business, risks, charges, expenses, and other information, which should be considered before investing. Obtain a Form C and Offering Memorandum at invest.smartnora.com. This is a paid advertisement for Smart Nora, LLC's Reg CF campaign.

Market Overview
Read time 1.4 minutes

Year To Date Performances:

Dow Jones  41,989.96 -1.30%
S&P 500  5,633.07 -4.23%
Nasdaq  17,449.89 -9.64%
Russell 2000 2,012.24 -9.77%
TSX  25,033.28 1.23%
Bitcoin $84,628.31 -8.39%
Ethereum $1,869.83 -43.85%
US to Canadian Dollar $1.43 -0.50%
  1. White House trade adviser Peter Navarro claims tariffs could generate $600–700 billion annually, but economists say the real figure is likely less than half that. A proposed 20% tariff on imports could theoretically yield $660 billion based on 2024 trade figures, but analysts argue that economic slowdowns, reduced consumer demand, and foreign retaliation will cut revenue significantly. Yale Budget Lab estimates a more realistic $250 billion per year. The White House also claims that tariffs can replace income tax; however, since tariffs are being issued via executive order, experts doubt they’ll last a decade, weakening their role in funding Trump’s proposed tax cuts.

  2. Hims & Hers shares rose 5% after announcing it will offer Eli Lilly’s weight-loss drug Zepbound, diabetes drug Mounjaro, and generic liraglutide on its platform. The company has navigated supply and regulatory challenges in the booming GLP-1 market, previously benefiting from compounded semaglutide sales before FDA restrictions limited its availability. While expanding its weight-loss portfolio, Hims & Hers expects $725 million in revenue from the segment, excluding compounded drugs, and is lobbying to maintain access to compounded treatments. The stock is up 27% this year after a 172% surge in 2024.

  3. Mortgage rates remain nearly unchanged, with the average 30-year fixed rate dipping slightly to 6.70% from 6.71%, while mortgage demand shows mixed signals. Purchase applications rose 2% for the week and are up 9% year-over-year, reflecting growing homebuyer interest amid increased inventory. However, refinance applications fell 6% but remain 57% higher than a year ago due to a low base effect. Markets remain cautious as uncertainty over potential tariffs keeps mortgage rates in a tight range.

  4. Headlines

    1. Israel plans to seize parts of Gaza in the latest military operation announced yesterday.

    2. Republicans won both special congressional elections in Florida.

    * This is sponsored content.

Are you looking to grow your business? Here is how I can help: 

📱Book a Strategy Call to get 1:1 feedback on your pitch, pitch deck and/or fundraising strategy. (If you need general startup advice, then reply to this email, and I’ll let you know if/how I can help.)

Tariffs Surge — This Tech Disruptor Moves Faster Than Global Shifts

Consumer electronics may have dodged the tariff bullet, but one smart home disruptor isn’t waiting for luck.

They’ve strategically secured production outside China, staying ahead of the global manufacturing shift.

That’s exactly how this company has hit 200% year-over-year growth while expanding into over 120 major retail locations.

Their smart shade technology is reshaping home automation, protected by patents and backed by powerful retail partnerships.

Smart investors spot the pattern: companies that turn global challenges into strategic wins often deliver the biggest returns.

At just $1.90 per share, you’re looking at a company that’s not just prepared for supply chain shifts — it’s already capitalizing on them.

Past performance is not indicative of future results. Email may contain forward-looking statements. See US Offering for details. Informational purposes only.

Onwards and Upwards,

Persuade & RaiseLearn how to become a VC-Backed Founder